Skip to content

Collect Digital Data

Opportunity

Participants expect a simple and convenient experience participating on clinical trials. To accomplish this goal, sponsors should consider the type, design and delivery of device (e.g., personal device,  provided by study, etc.) for participants to achieve accessibility, flexibility, convenience and maintain privacy. 

Considerations to Help Action the Opportunity

  • Understand if the clinical trial design supports the applications of digital patient solutions
  • Understand the needs and preferences of the participants taking part in the trial
    • Does the population have access to devices and data plans, or would they need these to be provisioned?
    • What devices would participants already have that could be used for clinical trials (e.g., wearables / sensors, glucometers, weighing scales, phones / tablets, etc.​)?
    • Understand impact on health equity (i.e., geographic, socioeconomic barriers) when implementing digital solutions 
  • Partner with sites to gain their input on the impact of multiple services, training, and technology implementation
  • Understand how the device may impact data integrity, regulatory landscape, site implementation and overall costs  
  • Define how technology is designed, communicated and delivered for / to participants
  • Define backup options (e.g., when a participant is unable to connect to device)

Value and Potential Benefits

  • Increases access and ease of participation for participants on clinical trials by potentially reducing the number of site visits
  • Allows for more robust datasets with improved data compliance and quality by enabling direct entry and near real-time review of data

Related Blog Posts

More 2026 Clinical Predictions

This is part 2 of my article about predictions for the clinical trials industry in 2026. From my reporting on AI growing pains, site-network shakeups, and the never-ending sponsor–site tension over feasibility and budgets, it’s clear the industry is carrying plenty of unresolved business into the new year. Read the full article featuring Rob DiCicco…

2026 Forecasts From People Smarter Than Me – Part 1

2026 will be defined by uncertainty — geopolitical instability, volatile global markets, and shifting health policies will influence every choice pharma companies make. From clinical trial planning to pipeline priorities, leaders will increasingly weigh innovation against risk, trying to preserve momentum while navigating an unpredictable global landscape. Read the full article featuring Allison Cuff Shimooka…

Nearly a third of clinical trial procedures may not drive results

Clinical trial protocols are among the most complex and resource-intensive documents developed in pharmaceutical and biotechnology research. Designed to define objectives, procedures, participant criteria, and data collection practices, protocols serve as the operational blueprint for evaluating investigational therapies. However, as the range of study endpoints has grown, so too has the volume, complexity, and burden…